Magurol

Doxazosin, the active ingredient in Magurol, is a alpha‑1 adrenergic blocker presented as an oral dosage form for oral use. It is indicated for the management of hypertension and for relief of urinary symptoms associated with benign prostatic hyperplasia in adult patients. GNH USA supplies Magurol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the vascular and prostatic smooth muscle to lower blood pressure and improve urinary flow. - Hypertension: reduces systemic vascular resistance and lowers elevated blood pressure. - Benign prostatic hyperplasia (BPH): relaxes prostate and bladder neck smooth muscle, improving urinary symptoms such as hesitancy and weak stream.

Doxazosin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or tiredness. - Nasal congestion. - Peripheral edema. - Nausea.

Serious or Rare Side Effects: - Severe orthostatic hypotension or syncope. - Priapism. - Liver function abnormalities. - Angioedema. - Severe allergic reactions such as rash or urticaria.

Before initiating therapy with Doxazosin, consider the following precautions. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Orthostatic assessment: advise patients to rise slowly to reduce dizziness. - Renal and hepatic function: evaluate before dosing and adjust if impairment is present. - Cardiac disease: use cautiously in patients with heart failure or recent myocardial infarction. - Discontinuation: avoid abrupt cessation; taper if long‑term therapy is stopped. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other antihypertensives may cause additive hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can increase plasma concentrations. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) may precipitate severe hypotension. - Lithium: enhanced lithium levels and toxicity risk. - Alpha‑agonists (e.g., phenylephrine) may counteract therapeutic effect.

Moderate Interactions (Monitor Closely):\n- Diuretics: may amplify orthostatic blood pressure drops. - NSAIDs: can blunt antihypertensive response. - Beta‑blockers: monitor for combined cardiovascular effects. - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Antidepressants affecting norepinephrine (e.g., venlafaxine) may alter response.